These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 4468232)

  • 1. Derivatives of fibrinogen and fibrin during defibrase therapy. Separation of high and low molecular weight derivatives of fibrinogen and fibrin by agarose gel filtration.
    Asbeck F; Lechler E; Martin M; van de Loo J
    Haemostasis; 1974; 3(5-6):340-7. PubMed ID: 4468232
    [No Abstract]   [Full Text] [Related]  

  • 2. [Studies on blood coagulation systems during defibrinogenation therapy with batroxobin (Bothrops atrox venom) (author's transl)].
    Ishimaru S; Konishi M; Furukawa K; Takahashi M; Fujimaki M
    Rinsho Ketsueki; 1979 May; 20(5):500-9. PubMed ID: 465131
    [No Abstract]   [Full Text] [Related]  

  • 3. [Defibrination-therapy using a thrombin-like snake venom enzyme (Defibrase) Blood-coagulation physiological studies and clinical experiences].
    Martin M; Engelken HJ; Tambert F; Martin U; Hirdes E; Auel H
    Vasa Suppl; 1976; 5():1-39. PubMed ID: 1070197
    [No Abstract]   [Full Text] [Related]  

  • 4. Experience of extensive vascular surgery on defibrase-defibrinogenated patients.
    Olsson P; Blombäck M; Egberg N; Ekeström S
    Thromb Res; 1976 Sep; 9(3):277-87. PubMed ID: 982350
    [No Abstract]   [Full Text] [Related]  

  • 5. The influence of drugs on disseminated intravascular coagulation (DIC). IV. Effects on the thrombin-like enzyme batroxobin on thrombin-induced DIC in rats.
    Markwardt F; Nowak G
    Thromb Res; 1980 Jan 1-15; 17(1-2):103-11. PubMed ID: 6990544
    [No Abstract]   [Full Text] [Related]  

  • 6. Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive technique.
    Connaghan DG; Francis CW; Lane DA; Marder VJ
    Blood; 1985 Mar; 65(3):589-97. PubMed ID: 3971042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic lowering of fibrinogen levels].
    Ernst E
    MMW Munch Med Wochenschr; 1983 May; 125(21):83-4. PubMed ID: 6410202
    [No Abstract]   [Full Text] [Related]  

  • 8. [Reduction of hyperfibrinemia in the nephrotic syndrome using defibrase].
    Salvadori JM; Follana R; Olmer M
    J Urol Nephrol (Paris); 1975 Sep; 81(9):691-6. PubMed ID: 1214313
    [No Abstract]   [Full Text] [Related]  

  • 9. [Familial dysfibrinogenemia with abnormal nonomer aggregation. Paris III fibrinogen].
    Soria J; Soria C
    Pathol Biol (Paris); 1974 Nov; 22 suppl():72-9. PubMed ID: 4620099
    [No Abstract]   [Full Text] [Related]  

  • 10. Hemodilution combined with defibrinogenation.
    Böhme H; Everts B
    Bibl Haematol; 1981; (47):165-72. PubMed ID: 7039611
    [No Abstract]   [Full Text] [Related]  

  • 11. The cleavage sequence of fibrinopeptide A from fibrinogen fragment E by thrombin, atroxin or batroxobin.
    Meh DA; Siebenlist KR; Bergtrom G; Mosesson MW
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):107-12. PubMed ID: 8457636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prolonged thrombin time of nephrotic syndrome.
    Abshire TC; Fink LK; Christian J; Hathaway WE
    J Pediatr Hematol Oncol; 1995 May; 17(2):156-62. PubMed ID: 7749766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation with defibrase during prolonged extracorporeal circulation in the dog.
    Berglin E; Svalander ; Teger-Nilsson A-C ; William-Olsson G
    Scand J Thorac Cardiovasc Surg; 1976; 10(3):225-30. PubMed ID: 1006222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A comprehensive laboratory evaluation of changes in the fibrinogen molecule in the diagnosis of acquired coagulopathy conditions].
    Siatkovskiĭ VA; Azarova LA; Vasilenko PL
    Lab Delo; 1989; (8):45-8. PubMed ID: 2477628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study on high molecular weight fibrinogen/fibrin complex (HMWFC) (author's transl)].
    Suzuki S; Matsui N
    Rinsho Ketsueki; 1979 Aug; 20(8):901-9. PubMed ID: 502006
    [No Abstract]   [Full Text] [Related]  

  • 16. The stimulatory capacity of soluble fibrin prepared from high and low molecular weight fibrinogen on plasminogen activation.
    Halvorsen S; Skjønsberg OH; Godal HC
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):133-7. PubMed ID: 8457641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and clinical implications of heparin-associated false positive tests for serum fibrin(ogen) degradation products.
    Connaghan DG; Francis CW; Ryan DH; Marder VJ
    Am J Clin Pathol; 1986 Sep; 86(3):304-10. PubMed ID: 3751995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of defibrinogenation with batroxobin on endotoxin-induced disseminated intravascular coagulation in rats.
    Yoshikawa T; Murakami M; Furukawa Y; Takemura S; Kato H; Kondo M
    Thromb Res; 1983 Sep; 31(5):729-35. PubMed ID: 6359574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical implications of analyses of fibrinogen and fibrin-derivatives in DIC].
    Magari Y; Ito M; Itoga T
    Rinsho Ketsueki; 1986 Oct; 27(10):1992-2007. PubMed ID: 3820619
    [No Abstract]   [Full Text] [Related]  

  • 20. Zinc inhibits FPA release and increases fibrin turbidity.
    Marx G; Hopmeier P
    Am J Hematol; 1986 Aug; 22(4):347-53. PubMed ID: 3728455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.